1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004. 39:309–317.
Article
2. Weber JT. Community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2005. 41:Suppl 4. S269–S272.
3. Levine DP. Vancomycin: a history. Clin Infect Dis. 2006. 42:Suppl 1. S5–S12.
Article
4. Karchmer AW. Staphylococcus aureus and vancomycin: the sequel. Ann Intern Med. 1991. 115:739–741.
5. Fridkin SK, Hageman J, McDougal LK, Mohammed J, Jarvis WR, Perl TM, Tenover FC. Vancomycin-Intermediate
Staphylococcus aureus Epidemiology Study Group. Epidemiological and microbiological characterization of infections caused by
Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis. 2003. 36:429–439.
Article
6. LaPlante KL, Rybak MJ. Impact of high-inoculum
Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2004. 48:4665–4672.
Article
7. Kim SH, Kim KH, Kim HB, Kim NJ, Kim EC, Oh MD, Choe KW. Outcome of vancomycin treatment in patients with methicillin-susceptible
Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2008. 52:192–197.
Article
8. Stryjewski ME, Szczech LA, Benjamin DK Jr, Inrig JK, Kanafani ZA, Engemann JJ, Chu VH, Joyce MJ, Reller LB, Corey GR, Fowler VG Jr. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible
Staphylococcus aureus bacteremia. Clin Infect Dis. 2007. 44:190–196.
Article
9. Rybak MJ, Akins RL. Emergence of methicillin-resistant
Staphylococcus aureus with intermediate glycopeptide resistance: clinical significance and treatment options. Drugs. 2001. 61:1–7.
Article
10. Brook I. Inoculum effect. Rev Infect Dis. 1989. 11:361–368.
Article
11. Lamp KC, Rybak MJ, Bailey EM, Kaatz GW.
In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin. Antimicrob Agents Chemother. 1992. 36:2709–2714.
Article
12. Mercier RC, Houlihan HH, Rybak MJ. Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against
Staphylococcus aureus and
Enterococcus faecium. Antimicrob Agents Chemother. 1997. 41:1307–1312.
Article
13. Moise PA, North D, Steenbergen JN, Sakoulas G. Susceptibility relationship between vancomycin and daptomycin in
Staphylococcus aureus: facts and assumptions. Lancet Infect Dis. 2009. 9:617–624.
Article
14. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998. 26:1–10. quiz 11-2.
Article
15. Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis. 2007. 44:79–86.
Article
16. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement. CLSI document M100-S18. 2008. Wayne,PA: CLSI.
17. Craig WA, Andes DR.
In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models. Antimicrob Agents Chemother. 2008. 52:3492–3496.
Article
18. Craig WA, Andes DR, Stamstad T.
In vivo pharmacodynamics of new lipopeptide MX-2401. Antimicrob Agents Chemother. 2010. 54:5092–5098.
Article
19. Stratton CW. In vitro susceptibility testing versus in vivo effectiveness. Med Clin North Am. 2006. 90:1077–1088.
20. Woods DD. The relation of p-aminobenzoic acid to the mechanism of the action of sulphanilamide. Br J Exp Pathol. 1940. 21:74–90.
21. Stevens DL. The role of vancomycin in the treatment paradigm. Clin Infect Dis. 2006. 42:Suppl 1. S51–S57.
Article
22. Nannini EC, Stryjewski ME, Singh KV, Rude TH, Corey GR, Fowler VG Jr, Murray BE. Determination of an inoculum effect with various cephalosporins among clinical isolates of methicillin-susceptible
Staphylococcus aureus. Antimicrob Agents Chemother. 2010. 54:2206–2208.
Article
23. Gould IM. Is vancomycin redundant for serious staphylococcal infection? Int J Antimicrob Agents. 2010. 36:Suppl 2. S55–S57.
Article
24. Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, Dalovisio JR, Levine DP. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2009. 49:325–327.
Article
25. Nettey H, Haswani D, D'Souza M, Oettinger C.
In vitro antimicrobial effect of encapsulated vancomycin on internalized
Staphylococcus aureus within endothelial cells. Drug Dev Ind Pharm. 2007. 33:133–139.
Article
26. Carryn S, Chanteux H, Seral C, Mingeot-Leclercq MP, Van Bambeke F, Tulkens PM. Intracellular pharmacodynamics of antibiotics. Infect Dis Clin North Am. 2003. 17:615–634.
Article
27. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev. 2002. 15:167–193.
Article
28. Conly JM, Johnston BL. VISA, hetero-VISA and VRSA: The end of the vancomycin era? Can J Infect Dis. 2002. 13:282–284.
Article
29. Proctor RA, Kahl B, von Eiff C, Vaudaux PE, Lew DP, Peters G. Staphylococcal small colony variants have novel mechanisms for antibiotic resistance. Clin Infect Dis. 1998. 27:Suppl 1. S68–S74.
Article
30. Park YH, Lee DG, Chun HS, Park C, Park SH, Choi SM, Lee HK, Park YJ, Kim SY, Hur JA, Choi JH, Yoo JH, Kang JH, Shin WS, Kim CC. Once-daily dosing of arbekacin can suppress the formation of small colony variants of methicillin resistant Staphylococcus aureus in an in vitro pharmacodynamic infection model. Infect Chemother. 2006. 38:154–163.
31. Ekdahl C, Hanberger H, Hällgren A, Nilsson M, Svensson E, Nilsson LE. Rapid decrease of free vancomycin in dense staphylococcal cultures. Eur J Clin Microbiol Infect Dis. 2005. 24:596–602.
Article
32. Chambers HF. Crossley KB, Archer GL, editors. Parenteral antibiotics for the treatment of bacteremia and other serious staphylococcal infections. The staphylococci in human disease. 1997. New York: Churchill Livingstone, Inc.;583–601.
33. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; sixteenth informational supplement. CLSI document M100-S15. 2006. Wayne, PA: CLSI.
34. Chung G, Cha J, Han S, Jang H, Lee K, Yoo J, Yoo J, Kim H, Eun S, Kim B, Park O, Lee Y. Nationwide surveillance study of vancomycin intermediate Staphylococcus aureus strains in Korean hospitals from 2001 to 2006. J Microbiol Biotechnol. 2010. 20:637–642.
35. Howden BP, Ward PB, Charles PG, Korman TM, Fuller A, du Cros P, Grabsch EA, Roberts SA, Robson J, Read K, Bak N, Hurley J, Johnson PD, Morris AJ, Mayall BC, Grayson ML. Treatment outcomes for serious infections caused by methicillin-resistant
Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis. 2004. 38:521–528.
Article